🔗 Share this article

Given that the United States continues making unprecedented changes to its immunization recommendations, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by questioning Covid vaccines during the global health crisis and has concentrated on possible deaths after Covid vaccination in her recent tenure at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Program

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccination calendar in December, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with a large portion of the world with no evidence for improved outcomes. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric shot schedules in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, head of the FDA’s CBER – instead of medication approval.

Concerns Over Qualifications

The appointee has little discernible track record in medication creation, regulation or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “be deeply familiar with legal statutes and the research of medication creation”, said Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who headed the center have had.”

The drug center has an enormous workload at the agency, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There is also a biosimilars division, over-the-counter program and so forth, and each of these need to be looked after,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a significant leadership component to the role, which manages more than 5,000 personnel. “It is a huge management job, if you do it right,” Woodcock added.

Response and Disputed Programs

Regarding concerns about Dr. Høeg's qualifications and whether this selection represents greater collaboration among regulatory chiefs on immunizations, a representative stated that the “inquiries stem from flawed presumptions”.

“This background matches the responsibilities of her position,” the representative stated, pointing to the time Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious one-day drug-approval program that reportedly worried her former heads. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent regulations of all drugs, with the exception of vaccines.”

Documented History on Vaccines

Regarding immunizations, Høeg has a more established, if problematic, history, Howard have noted. She authored a analysis using unverified volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the new administration included altering regulations for novel immunizations and halting “non-essential” vaccines, she remarked following the vote on a online show. At the FDA, Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her beliefs and reverse-engineers to accommodate the data in a extremely misleading, dishonest way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|